Sponsors

IARC’s Mission: Cancer research for cancer prevention The International Agency for Research on Cancer (IARC) is the specialized cancer agency of the World Health Organization. The objective of the IARC is to promote international collaboration in cancer research. The Agency is inter-disciplinary, bringing together skills in epidemiology, laboratory sciences and biostatistics to identify the causes of cancer so that preventive measures may be adopted and the burden of disease and associated suffering reduced. A significant feature of the IARC is its expertise in coordinating research across countries and organizations; its independent role as an international organization facilitates this activity. The Agency has a particular interest in conducting research in low and middle-income countries through partnerships and collaborations with researchers in these regions. Causes and prevention of cancer Emphasis is placed on elucidating the role of environmental and lifestyle risk factors and studying their interplay with genetic background in population-based studies and appropriate experimental models. This emphasis reflects the understanding that most cancers are, directly or indirectly, linked to environmental factors and thus are preventable. The IARC Monographs Programme is a core element of the Agency’s portfolio of activities, with international expert working groups evaluating the evidence of the carcinogenicity of specific exposures. The Agency is also committed to studying approaches for the early detection of cancer and in evaluating prevention strategies. A global reference for cancer information The IARC has an important role in describing the burden of cancer worldwide, through co-operation with and assistance to cancer registries and in monitoring geographical variations and trends over time. Key publications include the Cancer Incidence in Five Continents series and GLOBOCAN. The classification of human tumours as reported in the WHO “Blue Book” series is an additional resource of value to cancer researchers and clinicians worldwide. In all cases the Agency strives to make its findings available to the widest possible audience. Global cancer biobank One of the products of IARC’s coordinating role is an increasingly important biobank with currently approximately 6 million samples from 600 000 subjects in total. This resource permits the application of innovative laboratory-based methodologies to study the causes, early detection and prevention of cancer through collaborative studies with many international partners. Education and training A core part of the Agency’s mission is education and training of cancer researchers worldwide. This is achieved through fellowships, courses and publications. Priority is given to training researchers from low and middle-income countries in the areas of cancer epidemiology and cancer registration. Producing evidence-based science for global cancer control policies The close working relationship between IARC and its parent organization, WHO, allows the research findings of the Agency to be translated effectively into timely policies for cancer control. This is manifest, for example, in co-operation in terms of reduction in tobacco use, implementation of vaccination against viruses associated with cancer causation, or in assessing the effectiveness of intervention strategies. IARC is not involved directly in implementation of control measures, nor does it conduct research on treatment or care of cancer patients.

More info to be added soon.

The HUG: Care, Teaching, and leading-edge Research The Geneva University Hospital (HUG) comprises eight public hospitals and two clinics. Theirs missions are to provide health care to the community in all medical specialties, to help train physicians and health professionals, and to conduct medical and clinical research. The HUG operate as a national reference centre for influenza, emerging viral infections, meningococcus, and transplant immunology, and are the national reference laboratory for histocompatibility. They are also a WHO Collaborating Centre in six areas, as well as Centres of Excellence in a number of sectors. The HUG treat 275,000 patients each year, with a capacity of 2,015 hospital beds, and employ 12.800 people. For more information on publications visit https://www.hug.ch/publications-hug www.hug.ch – presse-hug@hcuge.ch References: https://www.hug.ch/laboratoire-virologie/centre-national-reference-influenza-cnri https://www.hug.ch/centre-maladies-virales-emergentes http://www.meningo.ch/ https://www.hug.ch/nephrologie/unite-immunologie-transplantation https://www.hug.ch/en-bref https://www.hug.ch/centres

The Nordic Cancer Union (NCU) was founded in 1949. It is a collaborative body consisting of representatives from the Danish, Swedish, Finnish, Icelandic, Norwegian and Faroese cancer societies. NCU was established to enhance cooperation between the cancer societies in the Nordic countries. The strategies and priorities for NCU are stipulated for three-year periods by the NCU Board. They follow the rolling three-year presidencies hold by each cancer society in time. Currently, The Cancer Society of Finland holding the presidency for the term 2021 - 2023. The NCU Board meets three or four times annually. The meetings are a forum to facilitate discussion and information exchange about diverse activities at national levels. They also serve to decide on grants to be awarded by the NCU, both for scientific research (with participants from at least three Nordic countries) and for strategic projects (e.g., Covid-19 and cancer, Immigrants and cancer, Total cost of cancer) one million euro total each year. NCU is supporting Nordic cancer research collaboration through its research grants (bottom-up), while the strategic grants (top-down) are for supporting the strategic aims of the Nordic Cancer Union.

Cancer Research UK is the world’s largest independent funder of cancer research. Its vision is to bring forward the day when all cancers are cured. Since 1902 CRUK has found new ways to prevent, diagnose and treat cancer. CRUK-funded scientists’ pioneered early radiotherapy, developed some of the world’s top cancer drugs and discovered the tumour suppressor gene, p53. Its work has saved millions of lives across the world. CRUK invests $500m annually in world-leading research across all 200 different types of cancer, working with partners in Europe, North America and Asia to accelerate research progress. It provides information to those affected by cancer, works to increase cancer awareness, and uses its powerful, independent voice to keep cancer at the top of the political agenda. CRUK funds some of the world’s leading experts in tobacco research and is a key player in international tobacco control. It became a full UICC member in 1986.

For more than a century, MSD, a leading global biopharmaceutical company, has been inventing for life, bring forward medicines and vaccines for the world’s most challenging diseases. MSD is a trade name of Merck & Co., Inc., Kenilworth, N.J., USA. Through their prescription medicines, vaccines, biologic therapies, and animal health products, they work with customers and operate in more than 140 countries to deliver innovative health solutions. MSD also demonstrates their commitment to increasing access to healthcare through far-reaching policies, programs and partnerships. Today, MSD continues to be at the forefront of research to advance the prevention and treatment of diseases that threaten people and communities around the world - including cancer, cardio-metabolic diseases, emerging animal diseases, Alzheimer’s disease and infectious diseases including HIV and Ebola.

The Medicaid Cancer Foundation (MCF) is a vehicle created by Medicaid to support cancer patients, promote cancer awareness and drive community cancer campaigns for undeserved populace in Nigeria. We provide support to guide people through the cancer experience, bring them together to fight cancer—and work for a world in which our fight is no longer necessary

On October 12, 1968, the Nigerian Cancer Society (NCS) was founded with the objective to assist in the development of facilities for diagnosis and treatment of cancer, to educate the public on ther problems of cancer, and to conduct research in all aspects of cancer. Since its founding, the society has expanded beyond the original founding town of Ibadan, and branches now exist in six geo-political zones of Nigeria. NCS’ first major successful publication was in 1982 with the book “Cancer in Nigeria-the proceedings of the NCS conference held in December 1979.” Since 1970, Nigerian Cancer Society has been associate UICC member.